SA
MSGR

S&P 500, Nasdaq, Russell 2000 below the 200-day average · VIX 28.3 · elevated volatility

Overview →

Direxion mRNA ETF (MSGR) focuses on investing in companies involved in the development and commercialization of mRNA technology, which has gained prominence due to its role in COVID-19 vaccines. The ETF's competitive position is bolstered by its targeted exposure to a rapidly evolving biotechnology sector, primarily in the United States, with a focus on firms that are leveraging mRNA for therapeutic applications beyond vaccines.

Financial ServicesAsset Managementlow - The ETF has minimal fixed costs, as its expenses are largely variable and tied to management fees based on AUM.

Business Overview

01Management fees from ETF assets under management (AUM) - 100%

The ETF generates revenue primarily through management fees based on the total assets under management. Its competitive advantage lies in its specialized focus on mRNA technology, which attracts investors looking for exposure to innovative biotech solutions. The fund's structure allows for flexibility in investment strategies, enabling it to capitalize on market trends in the biotech sector.

What Moves the Stock

Performance of underlying mRNA companies, particularly those with successful clinical trials

Market sentiment towards biotech and healthcare innovation

Regulatory approvals impacting mRNA therapies

Fluctuations in overall market conditions affecting investor appetite for ETFs

Watch on Earnings
Total AUM growthExpense ratioPerformance relative to benchmark indices

Risk Factors

Technological disruption in biotech, with potential for new therapies to emerge that could overshadow mRNA applications

Regulatory changes affecting the approval process for mRNA products

Increased competition from other ETFs focusing on biotech or specific technologies

Market volatility impacting investor sentiment towards high-risk sectors

Low liquidity risk due to the nature of ETF structures

Potential for high redemption rates during market downturns

StructuralCompetitiveBalance Sheet

Macro Sensitivity

Economic Cycle

moderate - The ETF's performance is somewhat linked to the broader economic cycle, as healthcare spending can fluctuate with economic conditions.

Interest Rates

The ETF's valuation may be impacted by interest rates, as higher rates could reduce the attractiveness of growth-oriented investments in biotech, potentially leading to lower inflows.

Credit

minimal

Live Conditions
Dow Jones FuturesRussell 2000 FuturesS&P 500 Futures10-Year Treasury30-Year Treasury5-Year Treasury2-Year Treasury30-Day Fed Funds

Profile

growth - Investors seeking exposure to innovative biotech solutions and high-growth potential.

high - The ETF may exhibit high volatility due to the nature of biotech stocks and market sentiment.

Key Metrics to Watch
Total AUM
Performance of key holdings within the ETF
Market trends in biotech funding
Regulatory developments in mRNA technology
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.